Filed by newsfilecorp.com News Release For Immediate Release Orgenesis Appoints Leading Diabetes Expert, Camillo Ricordi, M.D., to Scientific Advisory Board White Plains, NY

Orgenesis Appoints Leading Diabetes Expert, Camillo

Ricordi, M.D., to Scientific Advisory Board

White Plains, NY November 27, 2012 Orgenesis Inc.

(OTCBB:ORGS) ( Orgenesis or the Company ), a development-stage company with a

novel therapeutic technology dedicated to converting a patient s own liver cells

into functioning insulin-producing cells as a treatment for diabetes, is pleased

to announce the appointment of Camillo Ricordi, M.D., to its Scientific Advisory

Considered one of the world s leading experts in cell

transplantation, Dr. Ricordi is the Stacy Joy Goodman Professor of Surgery,

Distinguished Professor of Medicine, Professor of Biomedical Engineering, and

Microbiology and Immunology at the University of Miami Diabetes Research

Institute. He also serves as Director of the Diabetes Research Institute Cell

Transplant Center and Responsible Head of the NIH-funded cGMP Human Cell

Processing Facility.

Among his many accomplishments, Dr. Ricordi developed the

automated method for islet cell isolation called the "Ricordi Method . He has

served as President of the Cell Transplant Society, Co-founder and Chairman of

the National Diabetes Research Coalition, Co-founder and President of the

International Association for Pancreas and Islet Transplantation and a member of

the council of the Transplantation Society. Dr. Ricordi has authored over 600

scientific publications and has been awarded 11 patents as an inventor. Dr.

Ricordi completed his graduate and post-graduate studies at the University of

Dr. Ricordi currently serves as Co-Editor in Chief of Cell

At the Diabetes Research Institute we are fully committed to

develop a biological cure for diabetes in the fastest and most efficient way

possible, helping scientists and their promising projects worldwide with the

highest collaborative spirit. I am glad to be able to assist Orgenesis to

further develop, assess and verify the potential of their promising technology.

If successful, the proposed strategy may answer the longstanding call for a

solution to restore normal insulin production in people with diabetes",

commented Dr. Ricordi. Accordingly, I am very pleased to be joining the

Orgenesis Scientific Advisory Board and look forward to contributing to their

efforts to advance this potentially breakthrough treatment.

We are honored to have Dr. Ricordi join our Scientific

Advisory Board, said Orgenesis CEO, Jacob BenArie. Dr. Ricordi brings a

tremendous amount of clinical and scientific expertise and we know that his

guidance will prove invaluable to Orgenesis.

About Orgenesis Inc.

Orgenesis (OTCBB: ORGS) is a development stage company with a

novel therapeutic technology that employs a molecular and cellular approach

directed at converting a patient's own liver cells into functional insulin

producing cells, as a treatment for diabetes. The Company believes that

converting the diabetic patient's own tissue into insulin-producing cells

overcomes the problem of donor shortage and removes the risk of transplant

rejection. If successful, this could mean the end of diabetes, as we now know

it. For more information visit: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements"

which are not purely historical. Such forward-looking statements include, among

other things, the expectations of management that our regeneration technology

can be developed as therapeutic treatment for diabetes, and that its success

will be a breakthrough towards the end of diabetes as we know it. No assurance

can be given that any of the events anticipated by the forward-looking

statements will occur or, if they do occur, what benefits the Company will

obtain from them. Actual results could differ from those projected in any

forward-looking statements due to numerous factors. Such factors include, among

others, the inherent uncertainties associated with new projects and development

stage companies, which include, without limitation, the potential failure of

development candidates to advance through preclinical studies or demonstrate

safety and efficacy in clinical testing and the ability to pass clinical trials

so as to move on to the next phase, our ability to retain key employees and our

ability to finance development or satisfy the rigorous regulatory requirements

for new medical procedures. Competitors may develop better or cheaper

alternatives to our products. These forward-looking statements are made as of

the date of this news release, and we assume no obligation to update the

forward-looking statements, or to update the reasons why actual results could

differ from those projected in the forward-looking statements. Investors should

refer to the risk factors disclosure outlined in our periodic reports filed from

time-to-time with the Securities and Exchange Commission.